• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Immunovant Reported Topline Results From Its Phase 3 Study Of Batoclimab In Myasthenia Gravis And Initial Results From Period 1 Of Its Phase 2B Study In Chronic Inflammatory Demyelinating Polyneuropathy

    Benzinga·03/19/2025 11:46:59
    Listen to the news
    • Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the higher dose arm (with 74% mean IgG reduction) and a 4.7 point improvement in the lower dose arm (with 64% mean IgG reduction)
    • Initial CIDP results from Period 1, following standard of care washout, demonstrate a mean improvement in the adjusted INCAT disability score of 1.8 across batoclimab arms and an 84% responder rate in those patients who achieved an IgG lowering greater than 70%
    • In both batoclimab studies, deeper IgG reductions correlated with better clinical outcomes across a range of assessments and timepoints
    • INDs active for both MG and CIDP with pivotal study initiations for lead asset IMVT-1402 in these indications expected imminently